InflaRx

97 articles about InflaRx

• InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update

  5/12/2022

  InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the three months ended March 31, 2022 and provided a business update.

• InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

  3/31/2022

  InflaRx N.V. announced today that the Phase III part of the Phase II/III PANAMO study with mechanically ventilated COVID-19 patients showed a relative reduction in 28-day all-cause mortality of 23.9% (vilobelimab 31.7% versus placebo 41.6%, p=0.094).

• InflaRx Reports Full Year 2021 Financial and Operating Results

  3/24/2022

  InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced financial and operating results for the year ended December 31, 2021.

• InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa

  3/17/2022

  InflaRx N.V. today reported that the Company has received a corrected advice letter from the U.S. Food and Drug Administration (FDA) related to its Phase III program with vilobelimab for the treatment of hidradenitis suppurativa (HS).

• InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting

  3/8/2022

  InflaRx N.V. announced that final data from the Company’s Phase IIa open-label study with vilobelimab in patients with pyoderma gangrenosum (PG) will be presented at the 2022 American Academy of Dermatology Association (AAD) Annual Meeting , being held March 25-29 in Boston, MA USA.

• InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa

  2/28/2022

  InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported that the Company has received an advice letter from the U.S. Food and Drug Administration (FDA) related to its Phase III program with vilobelimab for the treatment of hidradenitis suppurativa (HS).

• InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

  2/16/2022

  InflaRx N.V. today announced the start of the second dosing cohort of the vilobelimab and PD-1 checkpoint inhibitor, pembrolizumab, combination arm of the Phase II clinical trial in cutaneous squamous cell carcinoma (cSCC).

• InflaRx to Present at Annual SVB Leerink Global Health Conference

  2/8/2022

  InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 11th Annual SVB Leerink Healthcare Conference being held virtually February 14-18, 2022.

• 

  Global Roundup: Medtronic Acquires Affera, Inc to Expand Cardiac Ablation Line

  1/13/2022

  Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.

• InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor

  1/10/2022

  InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

  1/5/2022

  InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced the initiation of the Phase III program with vilobelimab in hidradenitis suppurativa patients with active draining tunnels.

• InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events

  1/5/2022

  InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several investor events.

• InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference

  11/11/2021

  InflaRx will present a corporate overview at the H.C. Wainwright 7th Annual Israel Conference. The session will take place virtually on Monday, November 15th  at 8:00 am EST/2:00 pm CET

• InflaRx Reports Third Quarter 2021 Financial & Operating Results

  11/5/2021

  InflaRx announced today financial and operating results for the three and nine months ended September 30, 2021.

• InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference

  11/3/2021

  InflaRx announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will present a corporate overview during a fireside chat at the Credit Suisse 30th Annual Healthcare Conference.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

  10/27/2021

  InflaRx N.V. announces positive data from the third cohort of patients in the Phase IIa open-label study with vilobelimab in Pyoderma Gangraenosum (PG).

• 

  Clinical Catch-Up: October 11-15

  10/18/2021

  It was yet another busy week for clinical trial announcements. Take a look.

• InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

  10/12/2021

  InflaRx N.V. announced today the completion of enrollment of the Phase III part of the Phase II/III vilobelimab study in severe COVID-19 patients.